Understanding and Treating Female Sexual Dysfunction: AN UPDATE ON CURRENT LITERATURE

September 26, 2017

Tuesday, October 3, 2017 - 8:00 p.m. EDT



Sheryl A. Kingsberg, PhD

Sheryl A. Klngsberg, Ph.D
Chie f, Division of Behavioral Medicine
Department of OB/GYN
MacDonald Women's Hospital
University Hospitals Cleveland Medical Center
Professor, Departments of Reproductive Biology and Psychiatry
Case Western Reserve Universtty School of Medicine
Cleveland, OH


James A Simon, MD

James A. Simon, MD, CCD, NCMP, IF, FACOG
Clinical Professor
George Washington University
Women's Health & Research Consultants®
Washington, DC

A CME activity provided by Evolve Medical Education LLC

Supported through an educational grant from Valeant Pharmaceuticals International.

Female sexual dysfunction (FSD) is an overall umbrella disease that may affect as many as 40 million women in the U.S., with prevalence rates cited from 30o/o to as high as 80%. The etiology of FSD, however, is less well-defined or understood. Comprising both physiological and p sychologic all aspects, FSD can manifest in a variety of ways. This educational activity will include discussions on the definition, prevalence,
diagnosis and related g uide lines for managing this disease state.


Upon completion of this activity, the participants will be better able to:

  • Discuss treatment options for women with female sexual dysfunction, including the first available medication for a specific type of female sexual dysfunction
  • Discuss the prevalence of female sexual d ysfunction and counseling programs
  • Evaluate the differences in definitions, severity criteria, and duration of disease for female sexual dysfunction


Important Links & Numbers

Refer A Patient

Call Direct 866-UH4-CARE (866-844-2273)
or 800-552-8338

Contact a UH Physician Liaison Team Member Direct

Transfer Referral Line

216-844-1111 or

UH Physician Portal

Request UH Physician Portal Access

Find a UH Facility